Home  >  News
Marketing + Font Resize -

PharmaMar to commercialize PM1183 with trade name of zepsyre

Madrid
Monday, June 19, 2017, 18:00 Hrs  [IST]

PharmaMar, a world-leading biopharmaceutical company, has announced that PM1183 (lurbinectedin), its third molecule of marine origin and analogue of Yondelis, will receive the trade name of Zepsyre.

Zepsyre is currently undergoing development for the treatment of solid tumours. This promising agent is currently in final stage for platinum-resistant ovarian cancer and small cell lung cancer. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), as regulatory agencies, require the trade name to be unique and is part of the evaluation and approval process before marketing the product.

After the positive results presented during the last ESMO and ASCO meetings about BRCA 2 -associated metastatic breast cancer and endometrial cancer, respectively, PharmaMar will initiate a pivotal phase III study in each indication.  

"We trust in the potential of Zepsyre as a therapeutic alternative due to its novel mechanism of action and the antitumoral activity observed in all clinical trials for different type of tumors," says Luis Mora, Managing Director Oncology Business Unit at PharmaMar.

Zepsyre is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |